Literature DB >> 26261540

Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.

Zhi-Xin Qiu1, Shuang Zhao1, Xian-Ming Mo2, Wei-Min Li1.   

Abstract

The surface marker PROM1 is considered one of the most important marker of tumor-initiating cells, and its high expression is believed to be an adverse prognostic factor in gliomas, medulloblastoma and in other malignancies. The aims of our research were to explore the expression profile of the PROM1 in non-small cell lung cancer (NSCLC) and to assess its possible role as a prognostic factor. The protein expression profiles were determined via immunohistochemical staining assay. The clinical prognostic values of protein expression were investigated with univariate and multivariate survival analysis. The quantitative variable PROM1 expression was dichotomized according to the best cutoff value obtained by the receiver operating characteristics (ROC) analysis. The protein level of PROM1 of NSCLC was higher compared with normal tissues, and the survival analysis demonstrated the positive membrane expression and combination of membrane/cytoplasm groups of PROM1 had worse prognosis than those negative expression groups. Also, multivariate Cox regression analysis showed membrane expression of PROM1 and lymph node invasion were the independent prognostic factors. The expression of PROM1 was significantly higher than normal tissue, and high levels of PROM1 membrane expression and combination of membrane/cytoplasm expression were associated with adverse prognosis.

Entities:  

Keywords:  CD133; PROM1; non-small cell lung cancer; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26261540      PMCID: PMC4525874     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  14 in total

1.  The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer.

Authors: 
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

Review 2.  Cancer stem cells.

Authors:  Craig T Jordan; Monica L Guzman; Mark Noble
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

3.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.

Authors:  S Miraglia; W Godfrey; A H Yin; K Atkins; R Warnke; J T Holden; R A Bray; E K Waller; D W Buck
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

5.  The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions.

Authors:  D Corbeil; K Röper; A Hellwig; M Tavian; S Miraglia; S M Watt; P J Simmons; B Peault; D W Buck; W B Huttner
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

Review 6.  Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?

Authors:  Jiri Neuzil; Marina Stantic; Renata Zobalova; Jaromira Chladova; Xiufang Wang; Lubomir Prochazka; Lanfeng Dong; Ladislav Andera; Stephen J Ralph
Journal:  Biochem Biophys Res Commun       Date:  2007-02-06       Impact factor: 3.575

7.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

Authors:  Elena Monzani; Floriana Facchetti; Enrico Galmozzi; Elena Corsini; Anna Benetti; Chiara Cavazzin; Angela Gritti; Andrea Piccinini; Danilo Porro; Mario Santinami; Gloria Invernici; Eugenio Parati; Giulio Alessandri; Caterina A M La Porta
Journal:  Eur J Cancer       Date:  2007-02-22       Impact factor: 9.162

8.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

9.  AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature.

Authors:  Christine A Fargeas; Denis Corbeil; Wieland B Huttner
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

10.  Stem cell marker CD133 affects clinical outcome in glioma patients.

Authors:  Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

View more
  11 in total

1.  Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Authors:  Kathleen Conway; Sharon N Edmiston; Joel S Parker; Pei Fen Kuan; Yi-Hsuan Tsai; Pamela A Groben; Daniel C Zedek; Glynis A Scott; Eloise A Parrish; Honglin Hao; Michelle V Pearlstein; Jill S Frank; Craig C Carson; Matthew D Wilkerson; Xiaobei Zhao; Nathaniel A Slater; Stergios J Moschos; David W Ollila; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2018-12-06       Impact factor: 8.551

2.  Acquisition of Cancer Stem Cell-like Properties in Human Small Airway Epithelial Cells after a Long-term Exposure to Carbon Nanomaterials.

Authors:  Chayanin Kiratipaiboon; Todd A Stueckle; Rajib Ghosh; Liying W Rojanasakul; Yi Charlie Chen; Cerasela Zoica Dinu; Yon Rojanasakul
Journal:  Environ Sci Nano       Date:  2019-05-24

3.  [Role of ovarian tumor stem-like cells sorted from human epithelial ovarian cancer SKOV3 cells in vasculogenic mimicry formation].

Authors:  Jun Liang; Huimin Xing; Xiaohua Wu; Lei Zhang; Jun Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

4.  MiR-29a-3p suppresses cell proliferation in laryngocarcinoma by targeting prominin 1.

Authors:  Jili Su; Eryong Lu; Lijuan Lu; Chao Zhang
Journal:  FEBS Open Bio       Date:  2017-03-18       Impact factor: 2.693

5.  The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.

Authors:  Engeng Chen; Zhiru Zeng; Bingjun Bai; Jing Zhu; Zhangfa Song
Journal:  Oncotarget       Date:  2016-08-30

6.  Molecular Changes of Lung Malignancy in HIV Infection.

Authors:  Jianghua Zheng; Lin Wang; Zenghui Cheng; Zenglin Pei; Zhiyong Zhang; Zehuan Li; Xuan Zhang; Dong Yan; Qianlin Xia; Yanling Feng; Yanzheng Song; Weiping Chen; Xiaoyan Zhang; Jianqing Xu; Jin Wang
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

7.  PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis.

Authors:  Subbroto Kumar Saha; S M Riazul Islam; Kyung-Sup Kwak; Md Shahedur Rahman; Ssang-Goo Cho
Journal:  Cancer Gene Ther       Date:  2019-06-05       Impact factor: 5.987

8.  Serum microRNA-135a as a diagnostic biomarker in non-small cell lung cancer.

Authors:  Yuanwu Zou; Chengbao Jing; Li Liu; Ting Wang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

9.  Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.

Authors:  Verena Tiran; Joerg Lindenmann; Luka Brcic; Ellen Heitzer; Stefanie Stanzer; Nassim Ghaffari Tabrizi-Wizsy; Elvira Stacher; Herbert Stoeger; Helmut H Popper; Marija Balic; Nadia Dandachi
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

Review 10.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.